Health

Hapbee Strengthens Leadership Team with Key Appointments; Provides Update on Shares-for-Debt Settlement

New leadership roles designed to fast-track Hapbee’s product strategy and accelerate product deployments September 12, 2025 21:00 ET  | Source:…

3 months ago

Aja Health And Wellness Inc. Provides Update on Delay in Filing Financial Statements

September 12, 2025 19:34 ET  | Source: Aja Health and Wellness Inc. Not for dissemination in the United States of…

3 months ago

Avicanna Announces Change in CFO

September 12, 2025 18:00 ET  | Source: Avicanna Inc. TORONTO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or…

3 months ago

Update on Information Relating to the General Meeting of September 30, 2025

Update on Information Relating to the General Meeting of September 30, 2025 61 Founding, Historical, Employee and Executive Shareholders of…

3 months ago

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 — September 11, 2025 20:00 ET  |…

3 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

September 11, 2025 17:01 ET  | Source: Achieve Life Sciences SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE)…

3 months ago

GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer

Scientific Advisory Board member, Dr. Noriyuki Kasahara, appointed Chief Scientific Officer of GenVivo, to accelerate the achievement of major clinical…

3 months ago

RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma

Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs…

3 months ago

Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101

Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101…

3 months ago

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program

The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program…

3 months ago